At Travere Therapeutics, we are in rare for life.

We come together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease.

Patients & Caregivers

Meet Lillie

On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies.

Pipeline

We continuously seek to understand the diverse perspectives of rare patients to courageously forge new paths that can make a difference in their lives and provide hope for today and tomorrow.

Patient Advocacy

Meet Tiffany

Meet Paul

We are committed to broad access for our FDA-approved therapies, and we provide personalized clinical support services through the Total Care Hub.

OUR Therapies

Therapeutic Areas

These are the conditions for which we have an approved therapy or a research and development program.

Peroxisomal Biogenesis Disorder-Zellweger Spectrum Disorder (PBD-ZSD)

Cerebrotendinous Xanthomatosis (CTX)

Cystinuria

Bile Acid Synthesis Disorders (BASD)

Focal Segmental Glomerulosclerosis (FSGS)

IgA Nephropathy (IgAN)

Classical Homocystinuria (HCU)

Alagille Syndrome (ALGS)

N-Glycanase 1 (NGLY1) Deficiency

We are dedicated to staying informed and engaged on topics that may impact the rare disease community, featuring community members and sharing what we learn. Find info at our Pathfinder.

Eric Dube Named EY Entrepreneur of the Year 2022 Pacific Southwest Award Winner

News

Ernst & Young today announced that our CEO Eric Dube has been named an Entrepreneur of the Year 2022 Pacific Southwest Award winner! This prestigious award recognizes exemplary leaders who lift up their employees and their communities and are focused on creating a better world for all. A panel of independent judges selected 13 winners out of the 40 finalists who were eligible for the award.

Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress

News

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase 3 PROTECT and DUPLEX studies of sparsentan in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), respectively, at the 59th European Renal Association (ERA) Congress. The Company and its collaborators will also present nonclinical data examining the renal protective effects of sparsentan compared to controls. ERA is being held live in Paris, France, and virtually May 19-22, 2022.

Read the full press release >

Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

News

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).

Read the full press release >

Stephanie

IgAN, Rare Life

In the spring of 2020, after a hike with her husband and kids, Stephanie’s legs swelled unfathomably. She took a video of herself pressing her fingers into her legs, showing how her fingers would sink into the skin.

Travere Therapeutics Reports First Quarter 2022 Financial Results

News

SAN DIEGO, May 5, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2022 financial results and provided a corporate update.

Read the full press release >

Travere Therapeutics Announces Plan for Chief Financial Officer Transition

News

SAN DIEGO , April 20, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that its chief financial officer Laura Clague, CPA, will retire after serving in this role for the past seven years. Ms. Clague will step down from the CFO position in August 2022 and will remain employed by the Company in an advisory capacity into 2023 to facilitate a smooth transition. Chris Cline, CFA, the Company’s current senior vice president of investor relations and corporate communications and a member of the senior leadership team, has been named Ms. Clague’s successor as chief financial officer, to be effective in August 2022.

Read the full press release >

View More Pathfinder Stories